Alternate Name(s):
ORBENIN®, TEGOPEN®, BACTOPEN®
Classification:
Antibiotic
Original Date:
August 2005
Revised Date:
January 2024
Indications:
- Semi-synthetic penicillin for infections due to susceptible beta-lactamase producing staphylococci
Reconstitution and Stability:
|
VIAL SIZE |
STERILE WATER for INJECTION REQUIRED |
FINAL CONCENTRATION |
|
500 mg |
4.9 mL |
100 mg/mL |
|
2,000 mg |
18.7 mL |
100 mg/mL |
- Reconstituted solution stable 24 hrs at room temperature or 7 days refrigerated
- Diluted solutions stable 28 days refrigerated (2.5-40 mg/mL)
Compatibility:
- Solutions Compatible: dextrose, 0.9% NaCl, ringer's solution
- Additives/Above Cassette Compatible: potassium chloride (up to 60 mmol/L)
- Y-site Compatible: potassium chloride (up to 60 mmol/L), amino acids and dextrose, morphine (up to 10mg/mL)
- Incompatible: lipids (fat emulsion)
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | YES, deep into muscle |
| IV Direct |
Usually not given due to vein irritation |
| IV Intermittent Infusion | YES Usual dilution: 20 mg/mL Infusion time: 30-60 minutes |
| IV Continuous Infusion | YES |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
PEDIATRIC:
- Mild-Moderate Infections: 100-200 mg/kg/day IV/IM ÷ Q4 - 6H (Max 2 g/dose)
- Severe Infections: 150-200 mg/kg/day IV/IM ÷ Q 4 - 6 H (Max 2 g/dose)
ADOLESCENT/ADULT:
- 1 - 2 g IV/IM Q 4-6 H; up to 2 g Q 4H
Potential hazards of parenteral administration:
- Hypersensitivity reaction (cross-sensitivity with other penicillins or cephalosporins)
- Skin rashes, urticaria
- Thrombophlebitis
- Possibility of seizures when large doses are administered in patients with renal impairment or when dose is infused too quickly
- Rarely eosinophilia, mild leukopenia, elevated SGOT, proteinuria, elevated BUN
Notes:
- Monitor CBC with differential, urinalysis, serum creatinine, BUN, liver enzymes